Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

CDKN2C Deletion on 1p32 Locus As Part of Irwazh Score, a New Risk Assessment Model for Venous Thromboembolism Occurring within 6-12 Months of Treatment Initiation in Newly Diagnosed Multiple Myeloma

Jean-Richard Eveillard, Nathalie Douet-Guilbert, Audrey Basinko, Romuald Kerdoncuff, Adrian Tempescul, Hussam Saad, Charazed Bekara, Zoé Bezagu, Moriamo Eniafe-Eveillard, Christophe Nicol, Jean-Christophe Ianotto

Blood (2023) 142 (Supplement 1): 4735.

https://doi.org/10.1182/blood-2023-179557

Published: 2023

Journal Articles

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Blood (2022) 140 (Supplement 1): 4379–4381.

https://doi.org/10.1182/blood-2022-158484

Published: 2022

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Enrique M. Ocio, MDPhD, Yvonne A. Efebera, MD MPH, Roman Hájek, MD PhD, Miquel Granell, MD, Vladimir Maisnar, MD, Jan Straub, MD, Jean-Richard Eveillard, MD, Lionel Karlin, MD, Vincent Ribrag, MD, María-Victoria Mateos, MD PhD, Albert Oriol, Malin Sydvander, MSc, Stefan Norin, MD, Sofia Mannikko, MSc, Luděk Pour, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-135991

Published: 2020

Journal Articles

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1836.

https://doi.org/10.1182/blood-2019-124484

Published: 2019

Journal Articles

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood (2018) 132 (24): 2555–2563.

https://doi.org/10.1182/blood-2018-07-863829

Published: 2018

Includes: Supplemental data

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood (2018) 132 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2018-99-111892

Published: 2018

Journal Articles

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Blood (2018) 132 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2018-99-112983

Published: 2018

Journal Articles

CKS1B/CDKN2C Copy Number Ratio : A New Predictor of Survival in Transplant- and Non Transplant-Eligible Multiple Myeloma Patients

Stéphanie Dos Santos, Hematologist in training, Laura Herbreteau, Christophe Nicol, Vincent Rebière, Hubert Galinat, Jean-Christophe Ianotto, MD PhD, Jean-Richard Eveillard

Blood (2018) 132 (Supplement 1): 2017.

https://doi.org/10.1182/blood-2018-99-118229

Published: 2018

Journal Articles

Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial

Blood (2015) 126 (23): 395.

https://doi.org/10.1182/blood.V126.23.395.395

Published: 2015

Journal Articles

Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial

Blood (2014) 124 (21): 3359.

https://doi.org/10.1182/blood.V124.21.3359.3359

Published: 2014

Journal Articles

Appraisal of IgM Kappa/IgM Lambda Variations Using HevyLite® After Rituximab As Consolidation Therapy in Patients with Waldenström's Macroglobulinemia

Jean-Richard Eveillard, MD, Achouak Achour, Françoise N'Go Sack, Adrian Tempescul, Ronan LE Calloc'h, Anaïg Dagorne, Annie Pietrantuono, MD, Daniel Chauvet, Boutahar Bendaoud, Christian Berthou, MD, Sophie Hillion, Yves Renaudineau, MD, PHD

Blood (2012) 120 (21): 4879.

https://doi.org/10.1182/blood.V120.21.4879.4879

Published: 2012

Journal Articles

Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study

Jean-Richard Eveillard, MD, Jean-Christophe Ianotto, Adrian Tempescul, Gaelle Guillerm, Florence Dalbiès, Hussam Saad, MD, Ronan LE Calloc'h, Anaïg Dagorn, Françoise N'go Sack, Christian Berthou, MD

Blood (2011) 118 (21): 3066.

https://doi.org/10.1182/blood.V118.21.3066.3066

Published: 2011

Journal Articles

Faisability and Results of Autologous Stem Cell Transplantation In Lymphoma Patients Over 65 Years Old.

Adrian Tempescul, Jean-Christophe Ianotto, Jean-Richard Eveillard, Gaelle Guillerm, Fontanet Delices Bijou, MD, Christian Berthou

Blood (2010) 116 (21): 4593.

https://doi.org/10.1182/blood.V116.21.4593.4593

Published: 2010

Journal Articles

Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 In Poor-Risk DLBCL: Results of a Phase II Study

Jean-Richard Eveillard, MD, Jean-Christophe Ianotto, Adrian Tempescul, Gaelle Guillerm, Hussam Saad, MD, Florence Dalbiès, Ronan Le Calloch, Anaïg Dagorne, Christian Berthou

Blood (2010) 116 (21): 3558.

https://doi.org/10.1182/blood.V116.21.3558.3558

Published: 2010

Journal Articles

Myelodysplatic Syndrom

Jean-Richard Eveillard, MD, Jean-Christophe Ianotto, Adrian Tempescul, Gaelle Guillerm, Le Calloch Ronan, Anaïg Dagorne, Christian Berthou

Blood (2010) 116 (21): 4980.

https://doi.org/10.1182/blood.V116.21.4980.4980

Published: 2010

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Pregnancy: The French Experience.

Sophie de Guibert, Régis Peffault de Latour, Nathalie Varoqueaux, Hélène Labussiere, Bernard Rio, Dominique Jaulmes, Jean-Richard Eveillard, Stéphanie Dulucq, Anne Marie Stoppa, Didier Bouscary, François Girodon, Bernard Bonnotte, Gérard Socié, Thierry Lamy

Blood (2009) 114 (22): 1984.

https://doi.org/10.1182/blood.V114.22.1984.1984

Published: 2009

Journal Articles

Peripheral Blood Stem Cell Collection in Elderly Patients

Adrian Tempescul, Jean-Christophe Ianotto, Jean-Richard Eveillard, Elisabeth Hardy, Gaelle Guillerm, Florence Dalbies, Christian Berthou

Blood (2008) 112 (11): 4139.

https://doi.org/10.1182/blood.V112.11.4139.4139

Published: 2008

NARROW

CDKN2C Deletion on 1p32 Locus As Part of Irwazh Score, a New Risk Assessment Model for Venous Thromboembolism Occurring within 6-12 Months of Treatment Initiation in Newly Diagnosed Multiple Myeloma

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

CKS1B/CDKN2C Copy Number Ratio : A New Predictor of Survival in Transplant- and Non Transplant-Eligible Multiple Myeloma Patients

Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial

Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial

Appraisal of IgM Kappa/IgM Lambda Variations Using HevyLite® After Rituximab As Consolidation Therapy in Patients with Waldenström's Macroglobulinemia

Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study

Faisability and Results of Autologous Stem Cell Transplantation In Lymphoma Patients Over 65 Years Old.

Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 In Poor-Risk DLBCL: Results of a Phase II Study

Myelodysplatic Syndrom

Paroxysmal Nocturnal Hemoglobinuria and Pregnancy: The French Experience.

Peripheral Blood Stem Cell Collection in Elderly Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only